According to FutureWise analysis the market for intravitreal (ivt) injectables in 2023 was US$ 15.7 billion, and is expected to reach US$ 27 billion by 2031 at a CAGR of 6.5%.
Intravitreal injection is a process where medicine is injected directly into the eye using a very fine needle. This method allows the medication to be placed right into the vitreous humour, the jelly-like substance inside the eye. It's used to treat various eye problems, such as age-related macular degeneration (AMD), diabetic retinopathy, and eye infections like endophthalmitis.
Compared to putting drops in your eyes, this injection provides a more direct way to deliver the medicine. The needle goes right past the layers of the eye, so the medicine can work where it’s needed most. Plus, because it focuses on the eye, it can help minimize potential side effects that might occur if the medicine were given through the bloodstream.
Wet age-related macular degeneration (AMD) causes vision loss because new, aberrant, leaky blood vessels begin to invade the retina, filling it with extra fluid and causing it to enlarge. A molecule known as VEGF, or vascular endothelial growth factor, is one of the key initiators of this blood vessel expansion. Many medications that prevent the activity of VEGF have been created over the past 15 years, lowering swelling, at least partially recovering eyesight, or maintaining the course of the disease. Anti-VEGF medications must be injected into the eye because they are big molecules and cannot be taken orally or used as eyedrops to achieve the desired effects. Intravitreal (IVT) injections are used to provide the medication because they are injected into the vitreous, which is located in front of the retina.
According to the research study conducted by FutureWise research analysts, the Intravitreal (IVT) Injectables Market is anticipated to attain substantial growth by the end of the forecast period.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=259%20&type=requestsample
Intravitreal (IVT) Injectables Market Segmentation:
By Drug Class
- Anti-VEGF
- Antibiotics
- Corticosteroids
- Antifungals
- Antivirals
By Indication
- Diabetic Retinopathy
- Macular Degeneration
- Endophthalmitis
- Retinal Vein Occlusions
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in the Intravitreal (IVT) Injectables Market:
- Alcon Pharmaceuticals
- Novartis
- Regeneron Pharmaceuticals Inc.
- Allergan
- Alimera Sciences
- Bristol Myers Squibb
- Bausch And Lomb
- F. Hoffmann-La Roche
- Thrombogenics
- Valeant Pharmaceuticals International
Buy now the latest version of this report:
https://www.futurewiseresearch.com/checkout.aspx?ReportId=259&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Intravitreal (IVT) Injectables Market By Drug Class, By Indication, By Distribution Channel and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
